Navigation Links
Infants With Rare Genetic Disease Saved by Cord Blood Stem Cells

d normally, according to Kurtzberg.

Kurtzberg said their treatment successes provide a strong argument for mandatory, universal screening of all newborns for the genetic lysosomal storage diseases. The major barrier to universal newborn screening is building an infrastructure to support widespread testing, she said. The cost of testing itself would be relatively low.

Although lysosomal storage diseases are rare ?fewer than 5,000 births combined out of 4 million per year in the U.S. ?they are best treated if patients are diagnosed and treated in early infancy, said Kurtzberg. In fact, transplantation in newborns yields the best long-term outcomes and newborns tolerate the transplants more easily than older babies and children.

"Time is of the essence in treating these children before symptoms progress and become irreversible," said Kurtzberg, director of Duke's Pediatric Blood and Marrow Transplant Program. "Delaying the transplant even a week or two can make a noticeable difference in a child's motor skills, so timely diagnosis and treatment is essential to preserving brain and motor function."

Children transplanted after onset of symptoms do stabilize but exhibit minimal neurologic improvement, said Maria Luisa Escolar, MD, of UNC-CH, whose team assessed the neurological, cognitive and physical development of each child with Krabbe Disease before and after transplant.

Escolar is lead author of the study and directs the Program for Neurodevelopmental Function in Rare Disorders at the Center for Development and Learning, UNC-CH. The program is dedicated to tracking the natural history and the effects of new therapies in children with rare diseases.

In the new study, eleven asymptomatic newborns (ages 12 to 44 days) and 14 symptomatic infants (ages 142 days to a year) were treated with unrelated donor umbilical cord blood. Cells from the donor "engrafted" or took hold in all of the patients. All of the asymptomatic newbo
'"/>

Source:Duke University


Page: 1 2 3 4

Related biology news :

1. Infants with Rare Genetic Disease Saved By Cord Blood Stem Cells
2. Antiretroviral Therapy May Prevent HIV Transmission From Breastfeeding Mothers To Infants
3. Infants can organise visual information at just four months
4. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
5. Genetically modified natural killer immune cells attack, kill leukemia cells
6. Ants Genetic Engineering Leads To Species Interdependency
7. Genetic Variation Visualization - From EMBL
8. Genetically modified rice in China benefits farmers health, study finds
9. Genetically Modified Natural Killer Immune Cells Attack, Kill Leukemia Cells
10. Genetic defects give the immune system the green light to attack the pancreas
11. Maine Researchers Find Exceptions to Old Rules of Genetic Inheritance
Post Your Comments:
(Date:12/3/2009)Have you ever felt overly upset by a social snubbing? Your genetics, not your friends, may be at fault. , Scientists have long known that opium-like painkillers, called opioids, relieve not only phys
(Date:12/3/2009)Spanish researchers have measured CO2 levels for the past three years in the troposphere (lower atmosphere) over a sparsely inhabited rural area near Valladolid. The results, which are the first of th
(Date:12/3/2009)UPTON, NY A team of scientists from the U.S. Department of Energy,s (DOE) Brookhaven National Laboratory, Harvard University, and the Indian Institute of Science has made a major step in understandin
Breaking Biology News(10 mins):CO2 levels rising in troposphere over rural areas 2Grooving down the helix 2Grooving down the helix 3Power Plate 28R 29 Opens Cutting Edge Studio in L A 49383 1Power Plate 28R 29 Opens Cutting Edge Studio in L A 49383 2Benefit of glinides is not proven 49380 1Benefit of glinides is not proven 49380 2Benefit of glinides is not proven 49380 37th annual 5BBC 5D2 Basel Computational Biology Conference Molecular Evolution June 18 19 2009 8899 17th annual 5BBC 5D2 Basel Computational Biology Conference Molecular Evolution June 18 19 2009 8899 27th annual 5BBC 5D2 Basel Computational Biology Conference Molecular Evolution June 18 19 2009 8899 3
...e investigating exactly how chemotherapy drugs kil...s and test the effectiveness of safer new agents. ...versity of Manchester,s Faculty of Life Sciences h...ti-mitotic drugs, which are used extensively for b...f drugs, which includes the agent taxol, has been ...
...imate change, researchers at BBSRC-supported Rotha...amaging aphids the peach-potato aphid (Myzus pers...er for every 1C rise in mean temperature for Janua...hid was caught on 25 April, which is almost four w...eported in BBSRC Business, the quarterly researc...
...erated in health care, computational biology, home... massive and unstructured data sets has proven cum...known as data and visual analytics is helping sift... put together individual pieces of a picture. , T...five-year grant to lead and coordinate a new initi...
Other Biology News:How chemo kills tumors: research to reduce side effects 2How chemo kills tumors: research to reduce side effects 3Aphids are sentinels of climate change 2Grant supports emerging field of massive data analysis and visual analytics 2Grant supports emerging field of massive data analysis and visual analytics 3Grant supports emerging field of massive data analysis and visual analytics 4
(Date:12/2/2009)COPENHAGEN, Dec. 2 The world,s first concept demonstration tires made with BioIsoprene technology, a breakthrough alternative to replace a petrochemically produced ingredient in the manufacture of
(Date:12/2/2009)CAMBRIDGE, Mass., Dec. 2 TechConnect World, an event bringing together the leaders in technology development and product integration in cleantech, nanotech, biotech and MEMS, announced the December 1
(Date:12/2/2009)QUEBEC CITY, Dec. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today annou
(Date:12/1/2009)INCLINE VILLAGE, Nev., Dec. 1 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced revenue guidance for the fourth quarter ended December 31, 2009 of approximately $57 million, as compared with
Breaking Biology Technology:The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3
...e and Introduces Q1 2008 Guidance, FRAZER, Pa., F...ed 2007 sales of $1.727 billion, compared to sales...,s previously issued,guidance. Basic loss per comm...ng the previously announced settlement reserve, am...adjusted income per common share for the,full year...
... Technology Leadership, INDIANAPOLIS, Feb. 12 Th...wholly owned subsidiary of The Dow Chemical,Compan...ade to investors,earlier today by Jerome Peribere,...as speaking at the Goldman Sachs Agricultural Chem...rced Dow AgroSciences,technology-based strategy of...
...Corporation (NYSE: CBM ) announced that it will r... results on Thursday, February 14, 2008 after,mark.../prnh/20000613/CAMBREXLOGO ), The Company will h...r,and full year 2007 financial results., ...s Conference Call, When: Friday, Februa...
Other Biology Technology:Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 2Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 3Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 4Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 5Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 6Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 7Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 8Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 9Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 10Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 11Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 12Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 13Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 14Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 15Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 16Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 17Dow AgroSciences' Success Presented to Wall Street 2
Mouse Anti-Yersinia pestis F1 antigen Monoclonal Antibody, Unconjugated, Clone 1.F.1 from Abcam
Rabbit Anti-L Kynurenine Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-P5 Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Drosophila Melanogaster Achaete protein Monoclonal Antibody, Unconjugated from Developmental Studies Hybridoma Bank
Biology Products: